DC-CIK Immunotherapy

BIOLOGICAL5 trials

Sponsors

Capital Medical University, The First People's Hospital of Changzhou, Shenzhen Second People's Hospital

Conditions

Breast CancerCancerCondylomata AcuminataMalignant TumorMesothelioma, Malignant

Phase 1

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

TerminatedNCT03393858

Capital Medical UniversityCancer, Mesothelioma, Malignant

Start: 2017-12-01End: 2022-06-30Updated: 2024-02-07

Phase 2

Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer

Active, not recruitingNCT02491697

The First People's Hospital of ChangzhouBreast Cancer

Start: 2016-02-29End: 2033-08-31Target: 400Updated: 2016-02-23

Unknown Phase

Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy

CompletedNCT01884168

Capital Medical UniversityMalignant Tumor

Start: 2013-03-31End: 2023-05-31Updated: 2024-02-07

Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy

CompletedNCT01906632

Capital Medical UniversityMalignant Tumor

Start: 2013-05-31End: 2023-06-30Updated: 2024-02-07

Safety and Efficacy of Immune Therapy for Condyloma

Shenzhen Second People's HospitalCondylomata Acuminata

Start: 2017-06-25End: 2019-06-30Target: 80Updated: 2017-06-29